Testing vigya

On a Thursday evening that felt like a misplaced Tuesday, I found a cat sitting outside my apartment door. It was grey, with a faint spiral pattern on its back, like someone had drawn it absent-mindedly during a long phone call.

“You’re late,” the cat said!

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Business

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C13

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C12

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C9

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C8

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

More from Archive

Test

Test

Test Regulatory Recap: Ireland To See Earlier Off-Patent Medicines Launches As A State Deal Passes - Clone - Clone-1

 

Also, Latest News From Europe, Canada, Saudi Arabia, Finland, China, And The US

Embracing China’s Brave New Pharmaceutical World! - Clone - Clone!

 
• By 

Already one of the world’s largest pharmaceutical markets, China has tremendous growth potential, but significant policy and market changes are rocking the basis of competition. Multinational biopharma corporations cannot succeed in this new environment unless they fundamentally reinvent their business models to adapt to sweeping change.